Camacho Arroyo María T, Rivas Paterna Ana B, Meneses Monroy Alfonso, Cabrera García Lourdes, Blázquez González Patricia, Mancebo Salas Noelia, Rodríguez Leal Leyre, Vargas Castrillón Emilio
University School of Nursing Cruz Roja Madrid, Universidad Autónoma de Madrid, Madrid, Spain.
Clinical Research and Clinical Trial Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Arch Argent Pediatr. 2023 Feb 1;121(1):e202102550. doi: 10.5546/aap.2021-02550.eng. Epub 2022 Oct 6.
Introduction. In pediatric intensive care units, a large number of drugs are used, many of which are prescribed for condition beyond those established in their summary of product characteristics (off-label and unlicensed drug prescriptions). The objective of this study was to describe drug use and estimate the prevalence of off-label and unlicensed drugs in a pediatric intensive care unit of a tertiary care Spanish hospital. Population and methods. Cross-sectional, observational study with a single cohort of children admitted to a pediatric intensive care unit. The study was conducted in 2017. Each drug prescription, its conditions of use and administration were reviewed. In addition, the summary of product characteristics of drugs used were analyzed in order to identify whether they were used according to their conditions of authorization, or whether they were used in an off-label or unlicensed manner. Results. The sample included 97 patients. At least one off-label or unlicensed drug was administered to 74.2% (n = 72) of patients; 23.8% (n = 243) corresponded to off-label prescriptions and 8.7% (n = 89), unlicensed prescriptions. A sub-analysis by age group showed that the age group that received a higher number of total prescriptions (n = 611) and a higher percentage of off-label and/or unlicensed drug prescriptions (38.4%) was under 2 years of age. Conclusions. Off-label and/or unlicensed drug prescription is a common practice in the pediatric intensive care unit. This study allowed us to document the complexity of therapeutics in children.
引言。在儿科重症监护病房中,会使用大量药物,其中许多药物的处方超出了其产品特性摘要中规定的适用情况(即超说明书用药和未获许可药物处方)。本研究的目的是描述一家西班牙三级护理医院的儿科重症监护病房中的药物使用情况,并估计超说明书用药和未获许可药物的流行率。研究对象与方法。对入住儿科重症监护病房的单一队列儿童进行横断面观察性研究。研究于2017年开展。对每张药物处方及其使用和给药情况进行了审查。此外,还分析了所使用药物的产品特性摘要,以确定这些药物是否按照其获批情况使用,还是属于超说明书用药或未获许可用药。结果。样本包括97名患者。74.2%(n = 72)的患者至少接受了一种超说明书用药或未获许可药物;23.8%(n = 243)为超说明书用药处方,8.7%(n = 89)为未获许可药物处方。按年龄组进行的亚分析显示,总处方数量较多(n = 611)且超说明书用药和/或未获许可药物处方比例较高(38.4%)的年龄组为2岁以下儿童。结论。超说明书用药和/或未获许可药物处方在儿科重症监护病房中是一种常见做法。本研究使我们能够记录儿童治疗的复杂性。